Relay Therapeutics Secures $159M from ATM Offering, Extends Cash Runway into 2029

summarizeSummary

Relay Therapeutics reported a significant increase in cash reserves to $642.1 million, extending its cash runway into 2029, driven by $137.1 million in net proceeds from an ATM offering in Q1 2026 and an additional $22.1 million in April 2026.

check_boxKey Events

• Significant Capital Raise

  The company generated $137.1 million in net proceeds from its At-The-Market (ATM) offering during the first quarter of 2026, with an additional $22.1 million in net proceeds in April 2026, totaling $159.2 million.

• Strengthened Cash Position and Runway

  Cash, cash equivalents, and investments increased to $642.1 million as of March 31, 2026, which is expected to fund operations into 2029.

• Improved Financial Performance

  Net loss decreased to $73.3 million in Q1 2026 from $77.1 million in Q1 2025, and total operating expenses decreased by $10.9 million year-over-year.

• Continued Clinical Progress

  The company continues to advance its lead product candidate, zovegalisib, which recently received FDA Breakthrough Therapy designation, and other pipeline programs.

auto_awesomeAnalysis

This quarterly report highlights a significant strengthening of Relay Therapeutics' financial position, primarily through a substantial capital raise via its At-The-Market (ATM) offering. The $137.1 million in net proceeds during Q1 2026, supplemented by an additional $22.1 million in April 2026, has boosted the company's cash reserves to $642.1 million and reaffirmed its cash runway into 2029. This capital infusion, coupled with reduced net losses and operating expenses, is crucial for a clinical-stage biotech, enabling continued development of its pipeline, including the recently designated Breakthrough Therapy candidate, zovegalisib. While the ATM offering introduces dilution, the enhanced financial stability significantly de-risks the company's operational outlook and ability to fund its strategic initiatives.